Last reviewed · How we verify
Posaconazole Delayed Release Oral Tablet
Posaconazole inhibits fungal cell membrane synthesis by blocking lanosterol 14α-demethylase, a key enzyme in ergosterol production.
Posaconazole inhibits fungal cell membrane synthesis by blocking lanosterol 14α-demethylase, a key enzyme in ergosterol production. Used for Prophylaxis of invasive fungal infections in high-risk immunocompromised patients, Treatment of oropharyngeal candidiasis, Treatment of invasive aspergillosis.
At a glance
| Generic name | Posaconazole Delayed Release Oral Tablet |
|---|---|
| Also known as | Noxafil |
| Sponsor | Cedars-Sinai Medical Center |
| Drug class | Triazole antifungal |
| Target | Lanosterol 14α-demethylase (CYP51) |
| Modality | Small molecule |
| Therapeutic area | Infectious Disease |
| Phase | FDA-approved |
Mechanism of action
Posaconazole is a triazole antifungal that selectively inhibits the cytochrome P450-dependent enzyme lanosterol 14α-demethylase in fungi. This blocks the synthesis of ergosterol, an essential component of the fungal cell membrane, leading to membrane instability and fungal cell death. The delayed-release formulation improves bioavailability and allows for more consistent plasma concentrations.
Approved indications
- Prophylaxis of invasive fungal infections in high-risk immunocompromised patients
- Treatment of oropharyngeal candidiasis
- Treatment of invasive aspergillosis
Common side effects
- Nausea
- Diarrhea
- Vomiting
- Headache
- Abdominal pain
- Elevated liver enzymes
Key clinical trials
- Pilot Study of Posaconazole in Crohn's Disease (PHASE4)
- Amphotericin Versus Posaconazole for Pulmonary Mucormycosis (PHASE2)
- Azoles Targeting Recurrent High Grade Gliomas (EARLY_PHASE1)
- Peripheral Blood Stem Cell Transplantation From Family Haploidentical Donors in Patients With Myelodysplastic Syndrome and Acute Leukemia Under Primary Prophylaxis With Posaconazole (PHASE2)
- HDM201 Added to CT in R/R or Newly Diagnosed AML (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: